Biopharmaceutical company Poolbeg Pharma (AIM: POLB) (OTCQB: POLBF) announced on Tuesday that it has received official notification from the Japanese Patent Office granting the Immunomodulator II patent application. This strengthens the company's intellectual property, specifically covering the pharmaceutical composition of POLB 001 for treating severe influenza in hospitalised patients when combined with antiviral compounds.

Following the granted patent for Immunomodulator I, announced on 20 September 2023, Poolbeg continues to build a robust IP portfolio. The worldwide license for POLB 001 in all human uses contributes to this, encompassing the treatment of severe influenza and hypercytokinaemia using p38 MAP kinase inhibitors. The company aims to broaden patent protection, including potential applications alongside cancer immunotherapies.

Poolbeg Pharma focuses on developing and commercializing innovative medicines for high unmet medical needs. The company's strategy involves leveraging clinical assets and marketed drugs to fund its pipeline development, creating significant value. With an experienced leadership team, including former members of Amryt Pharma plc, Poolbeg aims to replicate past successes and generate near-term revenues.

The clinical programs target large markets in cancer immunotherapies, infectious diseases and an oral GLP-1 agonist for obesity and metabolic conditions. Using a cost-effective development approach, Poolbeg utilises AI-led infectious disease programs to analyze human challenge trial data, identifying relevant drug targets and treatments for faster development and increased commercial appeal.